New study proposes metrics to refine perturbatio

Canadian healthtech integrates blood testing, we

Evvy co-founder explains how ignoring female bio

Pet longevity biotech boasts stem cell therapies

Atrogi’s oral candidate mimics exercise to pre

Khosla-backed company aims to double number of l

Buck Institute study reveals how sugar breakdown

Licensing agreement with Chinese biotech Mabwell

NFX General Partner Omri Drory discusses why lon

Immortal Dragons founder explains how a purpose-

Clinical stage ‘mitochondrial augmentation’

New analyses reveal widespread discrepancies in

Real-world data suggest GLP-1 drugs like Ozempic

Researchers propose protocol for standardizing l

New study maps aging markers in dogs and investi

Platform that predicts disease and phenotype dir

New Longitude Prize to award £7.

FastWave’s Sola IVL device completes first-in-

Company’s antibody profiling technology could

New review from global geroscience experts maps

Combining next generation sequencing with advanc

New review explores metformin’s expanding pote

Companies harness AI to identify drugs that targ

Small-scale study of once-daily oral drug demons

RenewalBio is targeting longevity with a unique

New white paper from second Roundtable explores

Company aims to enhance drug discovery by observ

Leopoldina issues policy paper urging integratio

Company lands $21m for ‘human-first’ drug di

Longevity Summit Dublin CEO Martin O’Dea on wh

CARs trained on Alzheimer’s antibodies can det

Fauna Brain enhances company’s ability to iden

Founders Longevity Forum gathered leading expert

Where longevity escapes velocity – Founders Lo

Beauty brand partners with longevity companies a

Gordian Bio CEO explains how a cutting-edge in v

Study aims to determine whether MKK4 inhibitor c

Led by figures from Oxford, Genomics England and

Companies join forces to discover and develop ne

Company’s latest product continuously monitors

Neurotech firm Somnee secures funding to scale p

Shift Bioscience identifies potent, pluripotency

New consumer longevity brand to support company’s clinical development of therapeutics based on proprietary resveratrol delivery platform. Clinical stage biotech Jupiter Neurosciences has officially launched a new line of consumer supplements designed to support health and performance, broadening its focus from clinical-stage pharmaceuticals into the consumer longevity market. The company is leveraging its proprietary micellar resveratrol delivery technology to the nutraceutical space, offering a range of supplements designed to enhance healthspan, cognitive clarity and metabolic resilience. The new supplement brand, called Nugevia, emerges from Jupiter’s primary focus on optimizing the therapeutic delivery of resveratrol to target neuroinflammation and combat neurodegenerative diseases. Resveratrol, a compound long recognized for its potential antiaging and anti-inflammatory effects, has been limited in its clinical utility due to poor bioavailability and adverse gastrointestinal effects at higher doses. Jupiter claims its proprietary platform, JOTROL, addresses these limitations through a micellar formulation that improves absorption while maintaining a strong safety profile. In clinical studies, the company says JOTROL demonstrated a ninefold increase in bioavailability without the gastrointestinal side effects typically associated with high-dose resveratrol. “The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,” said Jupiter CEO Christer Rosén. “By building…

NFX General Partner Omri Drory wonders why more

Preclinical data suggest Telomir’s oral drug m

RLS-1496 enters Phase 1 aiming to modulate GPX4

Acquisition expected to support strategic collab

Genomics co-founder explains why recent advances

From state legislation to Capitol Hill coalition

Sleep is important to our physical and mental heal